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1. Introduction
Multiple myeloma is a plasma cell malignancy characterized with clonal expansion of
malignant plasma cells within the bone marrow and followed by osteolytic bone disease. It
accounts for approximately 1% of all malignant diseases and represents about 10% of hema‐
tologic malignancies. Data from cloning and gene-sequencing studies strongly imply that the
malignant clone in MM arises from a late cell in B-cell development. Investigation of a patient
with suspected myeloma should include the screening tests. Electrophoresis of serum and
concentrated urine should be performed, followed by immunofixation to confirm and type
any M-protein present.
The common clinical presentations are fatigue and bone pain with or without associated
fractures or infection. Mechanical impacts like intraosseous tumor pressure, microfractures,
periost irritation, muscle spasm, nerve entrapment and compression of nerves by the collapsed
vertebrae are reasons of severe myeloma pain.
Radiographic skeletal survey and bone marrow aspiration and biopsy are performed for
diagnosis. Angtuaco EJ et al reported a radiologic review and explained that MR imaging bone
marrow surveys in patients with MM demonstrate the broad spectrum of involvement, the
results of treatment, the areas of potential complications, and the sites of focal disease for safe
bone biopsies [1].
Pain characteristics clinically can be summarised as, pain is worse in supine position, especially
at night or awakens from sleep, band like distribution around body, not relieved with rest and
nonsteroidal anti-inflammatory drugs (NSAIDS), associated symptoms like fever, weight loss
and progressive neurologic deficite in lower extremities. Somatic, visceral and neuropathic
components can be easily involved in myeloma pain [2].
Chronic pain is extremely prevalent among patients with cancer. According to studies cancer
pain can be relieved in more than 70% of patients using a simple opioid- based regimen.
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Whether there is a relatively lesser degree of opioid responsiveness in chronic cancer pain,
then adjuvant analgesics are neccessary. Adjuvant analgesics describe the drug with a primary
indication other than pain, but with analgesic properties in some painful conditions, they are
usually coadministered with analgesics (acetaminophen, NSAIDS, opioids) when treating
cancer pain. Common causes of chronic pain in cancer patients as multiple myeloma patients
are releated to peripheral neuropathy due to chemotheraphy, radiotheraphy and tumor
invasion, chronic postsurgical incisional pain, phantom pain, musculoskeletal pain, visceral
pain from viscera or tumor.
The pain is one of the most common symptoms at diagnosis experienced by myeloma patients
and it may also be an indicator of a subsequent relapse. Up to 67% of patients report pain at
diagnosis, although this may have been present for several months before [3]. At diagnosis,
pain may be due to the disease process itself (predominantly from destructive bone disease,
but occasionally from plasmacytomas directly affecting neural tissues), or it may signify a co-
morbidity (e.g. degenerative arthritis or osteoporosis).
Later in the course of the disease, pain often arises as a sideeffect of therapies, e.g. thalidomide
or bortezomib neuropathy. Particularly in older patients, it is important to always consider co-
morbidities, such as arthritis or osteoporosis, mimicking bony malignant pain; diabetes or
carpal tunnel syndrome mimicking peripheral neuropathy (PN); and postherpetic neuralgia
as a common cause of persistent pain.
Assessment of pain, should start with taking a history but may involve imaging by X ray, bone
scan, CT or MRI. Myeloma patients should be evaluated for the presence and severity of pain
regularly. Pain severity can be assessed by visual analogue scales (VAS), numerical rated scales
(NRS) or verbal rated scales (VRS) [4]. To diagnose the presence of neuropathic pain, the Leeds
assessment of neuropathic symptoms and signs scale (LANSS) can be used [5].
The pain is usually in constant and dull at first but, as the disease progresses, it becomes more
severe until it is agonizing and constant. Severity of pain may be particularly devastating and
can negatively affect the quality of patient life and their functional status. This should be
managed using a multi-modal, mechanism-based approach including evidence-based
pharmacological therapies alongside non-drug methods such as radiotherapy, bisphospho‐
nates, and where appropriate, interventional and psychological techniques.
The critical importance of pain management as part of routine cancer care has been forcefully
advanced by WHO, international and national professional organisations, and governmental
agencies.
American Pain Society Quality of Care Task Force reviewed recommendations for faciliating
improvements in the quality of cancer pain management.
• Recognize and treat pain promptly (emphasis on comprehensive assessment and impor‐
tance of preventive and prompt treatment based on evidence for neuroplasticity)
• Involve patients and families in pain management plan (emphasis on customization of care
and participation of patient in treatment plan)
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• Improve treatment patterns (eliminate inappropriate practices, provide multimodal
therapy)
• Reassess and adjust pain management plan as needed (respond not only to pain intensity
but to functional status and side effects)
• Monitor processes and outcomes of pain management (new standardized indicators and
comments about forthcoming national performance indicators)
According to the European Society of Medical Oncology (ESMO) clinical practice guidelines
with WHO ladder, general approach to management of cancer pain is,
STEP I: Mild pain (NRS: 1–4) is treated with non-opioid analgesics such as acetaminophen/
paracetamol or a NSAID
Paracetamol is a useful analgesic in cancer-related pain and other chronic pains and should be
prescribed at a dose of up to 1 gram qid (p.o. or i.v. in patients who cannot take oral medication,
e.g. because of vomiting or mucositis).
NSAIDS should be avoided apart from very short term use (eg 3-5 days) with acute severe
pain, eg bone fracture. They should not be used in the presence of renal impairment, and used
with extreme caution in myeloma patients in view of the risk of precipitating renal compromise
For patients with mild pain (<5/10), normal release tramadol is a reasonable choice of analgesic
agent. Tramadol has 1/5th the potency of oral morphine and the starting dose is 50mg 6 hourly
prn or qid. Codeine can also be used but it is a pro-drug of morphine, and 10-15% of the
population is unable to convert it into active morphine, leaving them with unacceptable
toxicity [6].
STEP II: Traditionally, patients with moderate pain (NRS: 5–7) have been treated with a
combination product containing acetaminophen plus a weak immediate-release opioid
For patients with mild to moderate pain or whose pain is not adequately controlled by
paracetamol or a NSAID given regularly by mouth, the addition of a step II opioid (eg, codeine
or tramadol; table 1) given orally might achieve good pain relief without troublesome adverse
effects. Alternatively, low doses of a step III opioid (eg, morphine or oxycodone; table 1) may
be used instead of codeine or tramadol.
STEP III: In severe pain (NRS: 8–10), morphine, oxycodone, and hydromorphone can use and
the data show no important differences between morphine, oxycodone, and hydromorphone
given by the oral route. Morphine is most commonly used. Oral administration is the preferred
route. If given parenterally, the equivalent dose is one-third of the oral medication. The buccal,
sublingual and nebulized routes of administration of morphine are not recommended because
at the present time there is no evidence of clinical advantage over the conventional routes.
Patients with chronic moderate (5-7/10) or severe pain (>7/10) can be started on tramadol as
above, but will usually need to go onto more potent opioids rapidly if they do not respond.
Hydromorphone or oxycodone, in both immediate-release and modified-release formulations
for oral administration are effective alternatives to oral morphine. Oxycodone is twice the
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potency of morphine and is associated with less drowsiness and hallucinations. For rapid
onset, the normal release preparation can be used 4-6 hourly or qid, but most patients even‐
tually prefer the convenience of the bd sustained release forms [7].
Methadone is a valid alternative but may be more complicated to use because of marked inter-
individual differences in its plasma half-life and duration of action. Methadone use should be
initiated by physicians with experience and expertise in its use. Strong opioids may be
combined with ongoing use of a nonopioid analgesic (step I). Patients presenting with severe
pain that needs urgent relief should be treated with parenteral opioids, usually administered
by the subcutaneous (s.c.) or intravenous (i.v.) route. Intramuscular injections are painful and
have no pharmacokinetic advantage.
Patches can be used to deliver either fentanyl or buprenorphine, both of which are very potent
opioids. Fentanyl causes significantly less nausea, sedation and constipation compared to
morphine [8]. When given the choice of fentanyl patches or oral morphine for chronic pain,
patients prefer the patches [9]. They are usually the treatment of choice for patients who are
unable to swallow, patients with poor tolerance to morphine and patients with poor compli‐
ance. Earlier worries regarding an inferior equipotency ratio of buprenorphine to oral mor‐
phine or of a ceiling effect and partial antagonistic effects of buprenorphine as compared with
fentanyl have not been substantiated by newer publications [10]. Buprenorphine often initially
causes nausea but this can be covered by the use of an anti-emetic such as metoclopramide
and is otherwise well tolerated.
Immediate-release and slow-release oral formulations of morphine, oxycodone, and hydro‐
morphone can be used for dose titration. The titration schedules for both types of formulation
should be supplemented with oral immediate-release opioids given as needed. When using
normal release oral medication, the dose can be titrated up daily by 30-50% until pain is
controlled or unacceptable side effects occur. With sustained release oral medication it is
Oral opioid Characteristics and comments
Codeine Step II drug only: use alone or in combination with
paracetamol;
daily doses ≥360 mg not recommended
Tramadol Step II drug only: use alone or in combination with
paracetamol;
daily doses ≥400 mg not recommended
Hydrocodone Step II drug only: used as a substitute for codeine in some
countries
Oxycodone Step II opioid when used at low doses (eg, ≤20 mg per day)
alone or in combination with paracetamol
Morphine Step II opioid when used at low doses (eg, ≤30 mg per day)
Hydromorphone Step II opioid when used at low doses (eg, ≤4 mg per day)
Table 1. Step II opioids
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advisable to wait 2-3 days between dose increments. With patches, doses should not normally
be increased at less than 3 days intervals.
With all sustained release analgesics, it is essential to offer the patient a normal release ‘rescue
medication’ for breakthrough pain. This is particularly important when breakthrough pain
occurs quickly and predictably. It is important to distinguish this kind of ‘incident pain’ from
pain arising from end of dose failure with sustained release medications, or spontaneous pains
associated with neuropathy or opioid-induced hyperalgesia [11]. The ‘breakthrough dose’ is
usually equivalent to +10% - 15% of the total daily dose. If more than four ‘breakthrough doses’
per day are necessary, the baseline opioid treatment with a slow-release formulation has to be
adapted. Normal release oxycodone or morphine can be used, at 1/6th of the current 24 hour
total opioid dose. However, often the absorption of these oral drugs can be too slow for
breakthrough pain.. Opioids with a rapid onset and short duration are preferred for break‐
through doses. Fentanyl has a high bioavailability via the transmucosal route, which has led
to the development of fast-acting (but short-lived) fentanyl formulations. These include
fentanyl lozenges (Actiq ®); buccal tablets (Effentora®); or sublingual tablets [12]. Nasal sprays
will also soon be available. Normally, a patient should not need to use more 2–3 of these
relatively expensive fentanyl formulations per day for breakthrough pain; if more are being
taken, either the background medication needs to be increased or the patient should be referred
to a specialist. There is no place for pethidine in the treatment of pain in myeloma.
In addition, there is also worth noting that the recommendations for opioids for breakthrough
of the EAPC. The pain exacerbations resulting from uncontrolled background pain should be
treated with additional doses of immediate-release oral opioids, and that an appropriate titration
of around-the-clock opioid therapy should always precede the recourse to potent rescue opioid
analgesics.  Breakthrough pain  (eg,  incident  pain)  can  be  effectively  managed with  oral,
immediate-release opioids or with buccal or intranasal fentanyl preparations. In some cases the
buccal or intranasal fentanyl preparations are preferable to immediate-release oral opioids
because of more-rapid onset of action and shorter duration of effect. Additionally, immediate-
release formulations of opioids with short half-lives should be used to treat pre-emptively
predictable episodes of breakthrough pain in the 20–30 min preceding the provoking manoeuvre.
With all opioids, it is important to offer the patient a laxative and to keep checking for the
development of constipation. Transdermal fentanyl and buprenorphine are associated with
reduced incidence of constipation [13]. It is not necessary to routinely prescribe an anti-emetic
with opioids, except for the first week when starting buprenorphine.
Respiratory depression is uncommon in patients treated chronically with opioids as long as
dose increments are made carefully as outlined above. With the initiation of opioids, it is
common to see a reduction in respiratory rate; however, this is usually balanced by changes
in tidal volume so that minute ventilation initially remains steady. Care needs to be taken in
patients with COPD or obstructive sleep apnoea, in whom the respiratory depression can occur
even with low doses of opioids. True respiratory depression caused by opioids is diagnosed
by a reduction in oxygen saturation (SaO2 < 90%) or by arterial blood gases. If this occurs,
naloxone can be given but care must be taken not to provoke a serious increase in pain. Advice
on future opioid dosing should be sought from a specialist in pain or palliative medicine.
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Recently a condition known as opioid-induced hyperalgesia has been consistently identified
in animal studies and has also been demonstrated to occur in human studies. This condition
is characterised by increasing reporting of pain in the presence of increasing opioid dosage.
The pain can be localised to the original lesion but is often generalised to adjacent dermatomes.
The skin in the affected area may show hyperalgesia (increased pain response on normal
painful stimulus) or allodynia (pain felt even on light touch). The treatment involves reduction
in the opioid dosage along with the introduction of an NMDA channel blocker such as
ketamine or methadone [14].
Most opioids cause dose-related sedation; however, fentanyl and oxycodone are associated
with reduced sedation compared to morphine [15]. Patients who experience intolerable
sedation due to opioids (or other drugs, e.g. thalidomide) may be considered for a trial of a
psychostimulant such as methylphenidate or modafanil; this should only be prescribed by a
specialist in palliative medicine. In patients with opioid-related neurotoxic effects (delirium,
hallucination, and myoclonus), dose reduction or opioid switching should be considered.
Patients receiving step III opioids who have side-effects and do not achieve adequate analgesia
that are severe, unmanageable, or both, might benefit from switching to an alternative opioid.
When switching from one opioid drug to another, dose conversion ratios can be recommended
with different levels of confidence (table 2). These conversion ratios are specific for patients in
whom analgesia from the first opioid is satisfactory. Therefore, when the opioid is switched
because of unsatisfactory analgesia, excessive side-effects, or both, clinical experience suggests
that the starting dose should be lower than that calculated from published equianalgesic ratios.
In all cases the dose needs to be titrated in accordance with clinical response.
For patients with continuing severe (>6/10) pain or those who are unable to tolerate analgesics
because of adverse effects, help should be sought from a specialist service such as the palliative
care team or chronic pain team.
Haematology teams should readily seek to share care of pain and other symptoms with local
palliative and supportive care teams. Patients at home can be seen by community or hospice‐
based palliative care teams. Hospital chronic pain teams should be consulted for severe pain
if palliative and supportive care teams are not available. Acute pain teams may be helpful if
the patient has an acute severe pain, e.g. bone fracture causing immobilization, which may
respond to interventional procedures, e.g. local nerve blockade or spinal delivery of opioids
and local anaesthetic. Orthopaedic surgeons or interventional radiologists are able to perform
cement vertebroplasty or kyphoplasty for uncontrolled pain arising from vertebral collapse.
Psychologists can help with patients who have severe anxiety overlying pain and with other
issues.
In many of multiple myeloma patients, musculoskeletal complications with enhanced bone
destruction lead to pain with pathologic fractures, spinal cord compression and radiculopathy.
Bone lesions result not only from the direct deposits of myeloma cells within the bone, but also
from the release of soluble factors by both the tumor and the microenvironment, resulting in
the stimulation of osteoclast activity and bone resorption. The inhibition of bone resorption
and hypercalcaemia can be reduced by the use of bisphosphonates. This class of drugs
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potentiate the effects of analgesics in improving myeloma bone pain with reducing bone
releated events, but not mortality.
Management of spinal pain is often conservative, in the absence of instability/neurological
compromise, orthopaedic, neurosurgical or interventional radiological advice should be
sought in cases of persistent/refractory pain. Vertebroplasty and kyphoplasty are alternative
options for controlling pain associated with vertebral collapse. Vertebroplasty and kypho‐
plasty are both vertebral body augmentation techniques of percutaneous injection of bone
cement to the vertebral bodies. They are best performed soon after the vertebra collapses and
may be ineffective if many months have elapsed. Both techniques carry the small risk of cement
leakage leading to pulmonary embolism and neural compromise. It is therefore important that
there is access to a spinal surgery service when these procedures are performed.
Vertebroplasty involves the percutaneous injection, under general anaesthetic and i.v. sedation
and using radiological imaging, of polymethacrylate bone cement or equivalent biomaterial
into the vertebral body. Several vertebrae can be treated simultaneously. The injection allows
local pain relief and bone strengthening but will not restore vertebral height. No randomized
studies on the use of vertebroplasty in myeloma have been published. However, a recent
review of 67 cases demonstrated improvements in pain (89%), mobility (70%) and use of opioid
analgesia (65%) [16].
Kyphoplasty involves the percutaneous insertion of a small, inflatable balloon into the
vertebral body; when inflated it produces a potential space. The balloon is then removed and
bone cement is injected to fill the cavity. Although more time consuming than vertebroplasty
the complication rates appear lower with similar potential benefits of both pain relief and
RELATIVE ANALGESIC RATIO STRENGTH OF THE
RECOMMENDATION FOR USE
Oral morphine to oral oxycodone 1.5 : 1 Strong
Oral oxycodone to oral
hydromorphone
4 : 1 Strong
Oral morphine to oral hydromorphone 5 : 1 Weak
Oral morphine to TD buprenorphine
(*)
75 : 1 Weak
Oral morphine to TD fentanyl (**) 100 : 1 Strong
(*) Example: 60 mg oral morphine to 35 μg/h TD buprenorphine (equivalent to 0.8 mg per 24 h).
(**) Example: 60 mg oral morphine to 25 μg/h TD fentanyl (equivalent to 0.6 mg per 24 h).
TD=transdermal.
Table 2. Relative analgesic dose ratios
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improved function to vertebroplasty but with reduced risk of cement leak. There is also the
potential to restore vertebral height but this only occurs in a minority of patients. At the present
time, the documented use of kyphoplasty in myeloma is limited to case reports and small case
series although outcomes in myeloma do appear comparable to those in osteoporosis [17, 18].
Many patients with myeloma have subclinical or even clinical peripheral neuropathy (PN) at
diagnosis, often due to co-morbidities. These patients are at risk of worsening PN when
exposed to potentially neurotoxic drug treatments, such as thalidomide and bortezomib. The
cause of PN in myeloma patients is multifactorial and when patients are assessed, it is
important to grade the degree of neuropathy using a recognized scale, such as the National
Cancer Institute (NCI), Common Toxicity Criteria [19], LANSS [20] or the Total Neuropathy
Score [21].
PN in myeloma patients can be subdivided as follows:
• Disease- or M protein-associated peripheral neuropathy
• Peripheral neuropathy related to co-morbidities
• Chemotherapy-induced peripheral neuropathy
Disease- or M protein-associated peripheral neuropathy: Spinal cord or nerve root compres‐
sion is a common neurological complication of myeloma due to compression by plasmacyto‐
ma, lytic or extramedullary disease and requires appropriate imaging and specific treatment
including a specialist opinion as to the need for surgical intervention or radiotherapy.
The reported prevalence of sensory PN may depend on the study cohort, the methods of
detection and the criteria used, with a recent study reporting rates of pretreatment sensory PN
in up to 20% of patients, and neuropathic abnormalities in as many as 54%. [22].
The cause of the neuropathy in many cases of myeloma is not clear and may be multifactorial,
and studies have also varied in relation to rates of small or large fibre or mixed PN. In those
cases where amyloidosis and toxicity due to chemotherapy are not the cause, the M protein
itself or other consequences of the underlying disease may play a part. Clinically, a symmet‐
rical, distal sensory/motor neuropathy inducing paraesthesiae and numbness in the hands and
feet is seen.
POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, M-protein and Skin abnormali‐
ties) syndrome and AL amyloidosis are more specialized situations, PN is a significant clinical
feature in 85–100% of patients affected by POEMS syndrome [23]. It is a consequence of axonal
degeneration and demyelination, typically distal, symmetrical and initially sensory, but as the
condition progresses, a disabling symmetrical weakness may develop.
PN affects 17% of patients with AL amyloidosis at diagnosis. The PN is typically axonal and
characteristically painful, distal and symmetrical and often associated with an autonomic
neuropathy. Cryoglobulinaemia is another recognized source of PN.
Peripheral neuropathy related to co-morbidities: Conditions such as diabetes mellitus, carpal
tunnel and other nerve compression syndromes, including chronic inflammatory demyelinat‐
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ing polyradiculoneuropathy, chronic renal failure and vitamin B12 deficiency, should be
actively sought and appropriately managed, with specialist input as needed.
Chemotherapy-induced peripheral neuropathy: Chemotherapy-induced peripheral neuro‐
pathy (CIPN), also known as treatment-emergent peripheral neuropathy, is a major aspect of
myeloma management. CIPN has been a long recognized complication of vinca alkaloid and
platinum-based treatments and may be significantly dose limiting, but these drugs are no
longer in regular use in myeloma. There is emerging evidence for the incidence and natural
history of PN due to novel therapies, including thalidomide-induced PN (TiPN) and bortezo‐
mib-induced PN (BiPN), which may be considered as distinct clinical entities.
TiPN may arise after prolonged administration of thalidomide, is mostly mild to moderate in
severity and appears to be a cumulative effect [24]. Initial symptoms include sensory changes,
such as paraesthesia and hyperaesthesia, motor symptoms and autonomic dysfunction. Later
effects include loss of vibration and joint position sense, which may lead to ataxia and progres‐
sive gait disturbance. Nerve conduction studies do not reliably predict the onset of significant
TiPN and do not necessarily correlate with the clinical findings. Reduction or temporary
discontinuation of the drug usually leads to a clinical improvement in the symptoms whereas
continuation of dose intense treatment in the face of neuropathy may cause permanent neuro‐
logical damage. Mileshkin et al and other investigators have recommended that thalidomide
therapy should not exceed 6 months as the risk of TiPN is unacceptably high [25].
BiPN is characterized by neuropathic pain and a lengthdependent distal sensory neuropathy
with suppression of reflexes. Motor neuropathy may follow and infrequently results in mild to
severe distal weakness in the lower limbs. There may also be a significant autonomic compo‐
nent, which manifests as dizziness, hypotension, diarrhoea or constipation and/or extreme
fatigue. It is thought to occur at a certain threshold (within five cycles but rarely beyond) of
treatment and may be more likely to occur within the setting of renal impairment, in keeping
with other therapy related toxicities in this setting. Electrophysiological testing reveals a mainly
distal sensorimotor axonal loss, with secondary demyelination. The symptoms of BiPN improve
or completely resolve in the majority of patients after a median of 3 months following discontin‐
uation of the drug, but in a proportion of cases, symptoms have taken up to 2 years to improve
[26]. Apart from a graded dose reduction or withdrawal [27], the only treatment for BiPN is
symptomatic relief. No effective prophylactic treatment is available and any use of nutritional
supplements should be restricted to low doses to avoid harm from excessive doses of pyridox‐
ine. In particular, caution should be exercized with supplements containing ascorbic acid, which
may inhibit the anti-myeloma effect of bortezomib [28].
An accurate neurological history should be taken from all patients prior to commencement of
neurotoxic agents and regularly during the course of therapy. Patients should be reviewed in
person at the start of each cycle to ensure that emergent symptoms are detected and acted
upon. Dose-reductions may be needed within a treatment cycle if symptoms are progressive,
so as to avoid the irreversible neurological damage that may result from waiting until the next
cycle to make a change.
Initial investigations should be tailored according to the history and examination. Vitamin B12
deficiency should be screened for periodically. Metabolic and autoimmune causes should also
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be considered. If there are prominent features of small fibre neuropathy, then AL amyloidosis
should be excluded by tissue biopsy or serum amyloid P scan; any further investigations, such
as electrophysiological studies or cerebrospinal fluid protein estimation, should be directed
by a neurologist.
The management of PN should include symptom control along with treatment of any poten‐
tially reversible causes. Identification and correction of Vitamin B12 deficiency is important
and optimal management of co-morbid causes, such as diabetes mellitus or alcohol excess,
may also improve tolerance of neurotoxic drugs. An awareness of the spectrum of symptoms
that herald CIPN is crucial. Such symptoms need to be carefully sought at each meeting with
the patient.
Careful monitoring of patients receiving bortezomib and prompt dose and schedule modifi‐
cations are essential. Temporary interruptions in therapy may also be beneficial, before
resuming on a new schedule/dose. Recent data from front line protocols incorporating
bortezomib suggest that a weekly regimen is as effective and associated with less neuropathy
than twice-weekly regimens [29]. Although, the twice weekly regimens of subcutaneous
bortezomib offers non-inferior efficacy to standard intravenous administration, with an
improved safety profile for peripheral neuropathy in patients with relapsed multiple myeloma
[30]. Continuation of dose intense treatment in the face of neuropathy may cause permanent
neurological damage. Measurement of lying and standing blood pressures weekly in patients
receiving bortezomib may detect autonomic neuropathy before it becomes a debilitating
problem for the patient. The administration of intravenous normal saline prior to each dose of
bortezomib may improve tolerance of the drug.
Neuropathic pain is often poorly responsive to standard analgesic regimes. There has been
very little research specifically in the management of painful CIPN, and that has mostly been
in solid tumours [31]. Opioids can be effective but if used alone in high dose are associated
withsignificant adverse effects [32]. A multimodal approach using opioids together with other
pain modulating drugs is now recommended [33]. Thus a calcium channel blocker should be
added early (e.g. gabapentin or pregabalin); it may be necessary to add a sodium channel
blocking agent, e.g. oxcarbazepine (carbamazepine should be avoided because of drug
interactions); or an SNRI, e.g. amitryptiline or duloxetine.
Several studies have shown that adding gabapentin to an opioid in patients with cancer-related
neuropathic pain can give improved analgesia with reduced adverse effects compared to using
either agent alone [34]. The response to gabapentin correlated with the severity of the under‐
lying neurotoxicity. Approximately 25% of patients receiving gabapentin experienced mild
somnolence, but none discontinued it. Note that gabapentin may be associated with myelo‐
suppression and so should be avoided around the time of stem cell transplant.
The haematologist who is not familiar with these agents should seek advice from the local
chronic pain or palliative care service. For patients with continuing severe pain in spite of
initiating these drugs or those who are unable to tolerate analgesics because of adverse effects,
specialist help is essential. They will advise on dose modifications and can also initiate
specialist options, such as ketamine, methadone or spinal analgesia.
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In addition, topical treatments may be of benefit. Capsaicin cream 0.075% acts on peripheral
nerve TRPV1 heat and pain receptors; menthol acts on TRPM8 receptors for cold and may both
be helpful in patients with „cold‟ or „hot‟ dysaesthesia respectively [35]. Emollients, such as
cocoa butter, may help some patients but the physiological mechanism is unclear. In other
forms of superficial neuropathic pains (e.g. post-herpetic neuralgia or scar pain), the sodium
channel blocker lidocaine can be used topically as a 5% plaster, applied to the affected area for
12 hours and then left off for 12 hours. Some patients obtain relief within a few days but the
peak effect is reached with 2-4 weeks [36].
Complementary therapy can be defined as therapies that are used alongside, or integrated
with, conventional health care. These differ from alternative therapies, which are designed to
be used in place of conventional therapy. However, a clear definition of what constitutes
complementary and alternative medicine has not yet been elucidated, and therefore discretion
must be exercised when interpreting guidance pertaining to these therapies.
Complementary therapy has a role in the management of multiple myeloma when used as
adjunct to conventional medicine. It improves patients’ perceived quality of life and ability to
cope with the effects of the disease. The development of an evidence-base to support comple‐
mentary therapy use in myeloma is in the early stages of development.
Patients with myeloma may express preference for complementary therapy and place value
in the role they have to play within the context of their cancer care plan – for the management
of both the psycho-social and physiological effects associated with myeloma. Patients may
value complementary therapy and the sense of control gained when they are used as part of
their cancer treatment plan. Consequently, patient choice should be informed and respected
by healthcare professionals in order to ensure the best overall treatment and care plan for
myeloma is delivered.
There is a dearth of scientific evidence to support the effectiveness of complementary therapy
in the management of myeloma; however, some studies have shown that complementary
therapy can help patients with myeloma to: manage their symptoms, live with altered body
image, promote relaxation, alleviate anxiety, reduce chemotherapy side-effects, improve sleep
pattern, reduce stress and tension, reduce psychological distress/provide emotional support
and improve well-being. Importantly, cancer patients using complementary therapy also
perceive an improved quality of life.
Some complementary therapies, such as acupuncture, have been submitted to more rigorous
evaluation and are acknowledged for their effective use in cancer treatment for the manage‐
ment of chemotherapy-associated nausea and vomiting. However, no convincing scientific-
evidence has emerged to date that shows complementary therapy slows cancer progression
[37].
The types of complementary therapies and frequency with which they are used by myeloma
patients vary considerably. Among the most common therapies are homoeopathy, touch
therapies such as aromatherapy, massage and reflexology, healing and energy therapies
such as reiki, spiritual healing and therapeutic touch, hypnosis and hypnotherapy, acupunc‐
ture, herbal medicines and dietary interventions [38].
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